Arcellx to be Acquired by Gilead Sciences for $115.00 Cash Plus $5.00 CVR

summarizeSummary

Arcellx, Inc. announced its definitive acquisition by Gilead Sciences for $115.00 cash per share plus a $5.00 CVR, a major event that provides a significant premium and clear future for the company's lead asset, anito-cel.

check_boxKey Events

• Definitive Merger Agreement

  Arcellx entered into a definitive agreement on February 22, 2026, to be acquired by Gilead Sciences for $115.00 per share in cash, plus one contractual contingent value right (CVR).

• Contingent Value Right (CVR) Details

  Each CVR represents the right to receive a contingent payment of $5.00 per CVR in cash, payable if anito-cel cumulative worldwide sales exceed $6.0 billion on or prior to December 31, 2029.

• Regulatory Progress for Anito-cel

  The FDA accepted the Biologics License Application (BLA) for anito-cel for relapsed or refractory multiple myeloma (rrMM) on February 20, 2026, with an anticipated PDUFA action date of December 23, 2026.

• Shareholder Support for Acquisition

  Key stockholders, including New Enterprise Associates and executive officers, collectively owning approximately 10.3% of outstanding shares, entered into tender and support agreements on February 22, 2026, agreeing to tender their shares.

auto_awesomeAnalysis

This 10-K filing confirms the definitive agreement for Gilead Sciences to acquire Arcellx, Inc. in a two-step transaction, including a tender offer at $115.00 per share in cash plus a contingent value right (CVR) of $5.00 per share. The CVR is contingent on anito-cel cumulative worldwide sales exceeding $6.0 billion by December 31, 2029. This acquisition provides a significant premium over the current stock price and offers a clear exit for shareholders, fundamentally altering the company's future. The deal is expected to close in Q2 2026, subject to customary closing conditions. The filing also highlights the positive regulatory progress of anito-cel with FDA BLA acceptance and a PDUFA date set for December 23, 2026, which is a key driver for the CVR's potential value. The termination of the at-the-market offering program is a direct consequence of this acquisition.